Purchase this article with an account.
A. Galor, S. J. Ference, A. D. Singh, M. S. Lee, G. H. J. Stevens, V. L. Perez, D. M. Peereboom; Blood Brain Barrier Disruption Maculopathy. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5237.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report on the development of visually significant maculopathy associated with blood brain barrier disruption therapy for the treatment of CNS lymphoma.
Chart review of twenty patients undergoing blood brain barrier disruption therapy for treatment of CNS lymphoma at the Cleveland Clinic. Patients with documented maculopathy included in analysis.
Seven of thirteen patients (54%) were identified with new macular RPE changes after blood brain barrier disruption treatment which developed at a rate of 0.30 per person-year. The RPE changes consisted of fine clumps of hyperpigmentation in the foveal region associated with variable degrees of RPE loss. These changes were bilateral but often asymmetric. Two patients had decreased visual acuity due to maculopathy. One patient had documented progression of maculopathy after completion of treatment.
Maculopathy is frequent after blood brain barrier disruption therapy.
This PDF is available to Subscribers Only